Sarepta Therapeutics (NASDAQ:SRPT) had its target price trimmed by Cantor Fitzgerald from $231.00 to $175.00 in a research report report published on Tuesday morning, The Fly reports. The firm currently has an overweight rating on the biotechnology company’s stock.
Several other equities analysts have also commented on the company. Morgan Stanley upped their target price on Sarepta Therapeutics from $165.00 to $220.00 and gave the company an overweight rating in a research note on Tuesday, July 9th. Zacks Investment Research upgraded Sarepta Therapeutics from a hold rating to a buy rating and set a $130.00 target price for the company in a research note on Wednesday, May 8th. Janney Montgomery Scott dropped their target price on Sarepta Therapeutics from $200.00 to $175.00 and set a buy rating for the company in a research note on Tuesday. Citigroup dropped their target price on Sarepta Therapeutics from $201.00 to $190.00 and set a buy rating for the company in a research note on Thursday, May 16th. Finally, Bank of America dropped their target price on Sarepta Therapeutics from $200.00 to $189.00 and set a buy rating for the company in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and twenty-one have assigned a buy rating to the stock. The stock currently has an average rating of Buy and an average price target of $197.78.
Sarepta Therapeutics stock opened at $93.61 on Tuesday. The stock has a fifty day moving average price of $139.42 and a 200 day moving average price of $130.16. Sarepta Therapeutics has a 52 week low of $90.24 and a 52 week high of $165.87. The company has a current ratio of 8.81, a quick ratio of 7.84 and a debt-to-equity ratio of 0.44.
Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Wednesday, August 7th. The biotechnology company reported ($3.74) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.08) by ($2.66). The business had revenue of $94.67 million during the quarter, compared to analyst estimates of $91.05 million. Sarepta Therapeutics had a negative net margin of 165.52% and a negative return on equity of 55.37%. The business’s revenue for the quarter was up 28.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.67) earnings per share. On average, analysts anticipate that Sarepta Therapeutics will post -4.94 earnings per share for the current year.
In other news, Director Richard Barry purchased 1,300 shares of the stock in a transaction on Monday, August 12th. The stock was purchased at an average price of $122.50 per share, with a total value of $159,250.00. Following the completion of the transaction, the director now owns 3,173,365 shares in the company, valued at $388,737,212.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Douglas S. Ingram purchased 16,252 shares of the stock in a transaction on Monday, August 12th. The shares were purchased at an average cost of $123.07 per share, with a total value of $2,000,133.64. Following the transaction, the chief executive officer now owns 424,405 shares of the company’s stock, valued at approximately $52,231,523.35. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 26,252 shares of company stock valued at $3,109,234. 6.60% of the stock is owned by company insiders.
A number of hedge funds have recently bought and sold shares of the business. International Biotechnology Trust PLC lifted its stake in shares of Sarepta Therapeutics by 89.1% in the second quarter. International Biotechnology Trust PLC now owns 26,100 shares of the biotechnology company’s stock worth $3,965,000 after acquiring an additional 12,300 shares in the last quarter. UBS Group AG lifted its stake in shares of Sarepta Therapeutics by 36.0% in the second quarter. UBS Group AG now owns 109,361 shares of the biotechnology company’s stock worth $16,617,000 after acquiring an additional 28,958 shares in the last quarter. Walleye Trading Advisors LLC acquired a new position in shares of Sarepta Therapeutics in the second quarter worth about $1,688,000. Amundi Pioneer Asset Management Inc. lifted its stake in shares of Sarepta Therapeutics by 26.0% in the second quarter. Amundi Pioneer Asset Management Inc. now owns 194,845 shares of the biotechnology company’s stock worth $29,607,000 after acquiring an additional 40,234 shares in the last quarter. Finally, Voleon Capital Management LP acquired a new stake in Sarepta Therapeutics during the second quarter valued at approximately $5,166,000. 93.59% of the stock is owned by hedge funds and other institutional investors.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.